Skip to content

KPV (Lysine-Proline-Valine)

Emerging evidence

Tripeptide fragment of alpha-MSH with anti-inflammatory and gut-support research. Not medical advice; consult a provider.

How KPV (Lysine-Proline-Valine) works

KPV may reduce inflammatory signaling and support gut mucosa. Evidence is emerging; always combine with provider advice and your own research.

Researched benefits

  • •Anti-inflammatory properties
  • •Gut barrier and mucosal support
  • •May modulate immune response

What it is studied for

  • •Inflammatory bowel and gut inflammation research
  • •Skin inflammation in some studies
  • •Recovery and inflammation modulation

Reported side effects and cautions

  • •Generally well tolerated
  • •Limited long-term data

Dosing protocol described in the literature

Dosage
500mcg
Frequency
Daily
Administration
Subcutaneous or Oral
Cycle
6-12 weeks

Anti-inflammatory properties

Work out the reconstitution for this dose →

Evidence rating: Emerging evidence

Some human data exists but the evidence base is limited — often small studies, narrow indications, or trials still under way.

Other peptides

BPC157TB500 (Thymosin B4 Acetate)Semaglutide (Ozempic / Wegovy)Tirzepatide (GLP-1/GIP dual agonist)CagrilintideRetatrutide + Cagrilintide (combination)

See every peptide in the library →

Educational information only. This page is not medical advice, not a prescription, and not a recommendation to use KPV (Lysine-Proline-Valine). Dosing figures describe what appears in published research and provider protocols — they are not instructions. Several compounds covered here are prescription medicines. Talk to a licensed healthcare provider before acting on anything you read.